ReviewActa parasitologica2026
Role of Microbiome and Bacterial Biofilms in the Pathogenesis of Cutaneous Leishmaniasis.
Review in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCutaneous leishmaniasis (CL) is a vector-borne parasitic disease characterized by chronic skin lesions. Emerging evidence has highlighted the critical role of the skin microbiome and bacterial biofilms in disease progression. This review discusses the current evidence supporting the involvement of the skin microbiome and bacterial biofilms in the pathogenesis of CL. It further examines the clinical significance of microbiota dysbiosis and bacterial coinfections, reviews emerging biofilm-directed adjunctive therapeutic strategies, and outlines key knowledge gaps for future translational research.
methodsThe available literature on the skin microbiome, bacterial biofilms, microbiota dysbiosis, bacterial coinfections, host immune responses, and emerging biofilm-directed adjunctive therapeutic strategies in cutaneous leishmaniasis was reviewed.
resultsCL lesions are associated with microbial dysbiosis characterized by an increased abundance of opportunistic bacteria including Staphylococcus and Streptococcus species. These alterations contribute to dysregulated host immune responses, including increased production of pro-inflammatory cytokines and enhanced neutrophil recruitment, thereby promoting disease progression and delaying wound healing. Biofilm formation within CL lesions represents an additional factor contributing to disease persistence. Biofilms protect bacteria from host immune defences and limit antimicrobial penetration, thus reducing therapeutic efficacy and contributing to treatment failure. The interplay among Leishmania, bacterial communities, and host immunity creates a complex polymicrobial microenvironment that exacerbates lesion pathology.
conclusionA deeper understanding of these complex interactions may enable the design of more effective therapeutic approaches directed at both the parasite and the polymicrobial wound environment.
Indexed as
Identifiers
42507249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.